The agenda includes:
Preparation of a position on the evaluation of the drug Jyseleca (filgotinib) under the drug programme B.55. “Treatment of patients with ulcerative colitis”.
Positions on the legitimacy of granting reimbursement approval for the medicinal product Ztalmy (ganaxolone) for the indication: drug-resistant epilepsy based on mutations in the CDKL5 gene (ICD-10: G40.8) in paediatric population.